S&P 500   4,050.83 (+0.57%)
DOW   32,859.03 (+0.43%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
S&P 500   4,050.83 (+0.57%)
DOW   32,859.03 (+0.43%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
S&P 500   4,050.83 (+0.57%)
DOW   32,859.03 (+0.43%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
S&P 500   4,050.83 (+0.57%)
DOW   32,859.03 (+0.43%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
NASDAQ:ACER

Acer Therapeutics - ACER Stock Forecast, Price & News

$0.75
-0.01 (-1.32%)
(As of 03/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.73
$0.79
50-Day Range
$0.67
$2.42
52-Week Range
$0.65
$4.56
Volume
321,439 shs
Average Volume
452,537 shs
Market Capitalization
$15.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Acer Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.61% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.71mentions of Acer Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.23) to $0.71 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.51 out of 5 stars

Medical Sector

902nd out of 1,009 stocks

Pharmaceutical Preparations Industry

439th out of 494 stocks


ACER stock logo

About Acer Therapeutics (NASDAQ:ACER) Stock

Acer Therapeutics, Inc. is a pharmaceutical company. engages in acquisition, development and commercialization of therapies for medical needs. Its product pipeline includes ACER-001 Edsivo and ACER-2820. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. The ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases. The company was founded on March 15, 1991 and is headquartered in Newton, MA.

Receive ACER Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acer Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACER Stock News Headlines

[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
ACER Feb 2023 2.500 call
Acer (ACER) to Report Q4 Earnings: What's in the Cards?
Acer Therapeutics
See More Headlines
Receive ACER Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acer Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACER Company Calendar

Last Earnings
11/19/2021
Today
3/30/2023
Next Earnings (Estimated)
5/15/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACER
Employees
35
Year Founded
2013

Profitability

Net Income
$-15,370,000.00
Pretax Margin
-5,909.44%

Debt

Sales & Book Value

Annual Sales
$1.26 million
Book Value
($0.12) per share

Miscellaneous

Free Float
16,813,000
Market Cap
$15.80 million
Optionable
Not Optionable
Beta
0.65

Social Links


Key Executives

  • Christopher Schelling
    President, Chief Executive Officer & Director
  • Tanya Hayden
    Chief Operating Officer
  • Harry S. Palmin
    Chief Financial Officer
  • Stacey Bain
    Vice President-Clinical Operations
  • Adrian Quartel
    Chief Medical Officer













ACER Stock - Frequently Asked Questions

How have ACER shares performed in 2023?

Acer Therapeutics' stock was trading at $2.51 at the beginning of 2023. Since then, ACER shares have decreased by 70.1% and is now trading at $0.75.
View the best growth stocks for 2023 here
.

Are investors shorting Acer Therapeutics?

Acer Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 338,200 shares, an increase of 14.4% from the February 28th total of 295,600 shares. Based on an average daily volume of 556,500 shares, the days-to-cover ratio is currently 0.6 days.
View Acer Therapeutics' Short Interest
.

When is Acer Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023.
View our ACER earnings forecast
.

How were Acer Therapeutics' earnings last quarter?

Acer Therapeutics Inc. (NASDAQ:ACER) released its earnings results on Friday, November, 19th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.05.

What is Jason Chen's approval rating as Acer Therapeutics' CEO?

64 employees have rated Acer Therapeutics Chief Executive Officer Jason Chen on Glassdoor.com. Jason Chen has an approval rating of 99% among the company's employees. This puts Jason Chen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Acer Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acer Therapeutics investors own include Novavax (NVAX), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Sarepta Therapeutics (SRPT), Advanced Micro Devices (AMD), Amarin (AMRN), VBI Vaccines (VBIV), NVIDIA (NVDA), Idera Pharmaceuticals (IDRA) and Inovio Pharmaceuticals (INO).

What is Acer Therapeutics' stock symbol?

Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."

Who are Acer Therapeutics' major shareholders?

Acer Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Nantahala Capital Management LLC (7.69%), Knott David M Jr (0.88%), Geode Capital Management LLC (0.60%), Meridian Wealth Management LLC (0.45%), Renaissance Technologies LLC (0.37%) and SVB Wealth LLC (0.07%). Insiders that own company stock include Chris Schelling, Donald Joseph and Steve Aselage.
View institutional ownership trends
.

How do I buy shares of Acer Therapeutics?

Shares of ACER stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acer Therapeutics' stock price today?

One share of ACER stock can currently be purchased for approximately $0.75.

How much money does Acer Therapeutics make?

Acer Therapeutics (NASDAQ:ACER) has a market capitalization of $15.80 million and generates $1.26 million in revenue each year. The biopharmaceutical company earns $-15,370,000.00 in net income (profit) each year or ($1.66) on an earnings per share basis.

Does Acer Therapeutics have any subsidiaries?
The following companies are subsidiares of Acer Therapeutics: Opexa Therapeutics Inc..
Read More
How can I contact Acer Therapeutics?

Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The official website for the company is www.acertx.com. The biopharmaceutical company can be reached via phone at (844) 902-6100, via email at hans@lifesciadvisors.com, or via fax at 281-872-8585.

This page (NASDAQ:ACER) was last updated on 3/30/2023 by MarketBeat.com Staff